MedPage Today on MSN18h
MIND Diet and Cognitive Decline; Gene Therapy for Parkinson's; Curbing MS Fatigue
A high dose of the investigational gene therapy AAV-GAD, which delivers the glutamic acid decarboxylase ( GAD) gene to the ...
MeiraGTx’s Parkinson’s gene therapy shows promise in Phase I/II study
The AAV-GAD bridging study met the primary endpoint of safety and tolerability, and showed early promise in Parkinson’s ...
MGTX Stock Up on Upbeat Efficacy Data From Parkinson's Disease Study
MeiraGTx Holdings ’ MGTX clinical bridging study of its gene therapy candidate, AAV-GAD, for treating Parkinson’s disease (PD) met its primary study objective of safety and tolerability. The stock ...
pharmaphorum1d
MeiraGTx plans to take Parkinson's gene therapy into phase 3
Shares in the Anglo-US biotech rose sharply after the announcement, which came off the back of new data showing that the AAV-GAD gene therapy met targets for safety and efficacy in the MGT-GAD-025 ...
Nasdaq6d
MGTX Stock Up on Upbeat Efficacy Data From Parkinson's Disease Study
MeiraGTx Holdings’ MGTX clinical bridging study of its gene therapy candidate, AAV-GAD, for treating Parkinson’s disease (PD) met its primary study objective of safety and tolerability.
MeiraGTx Holdings: Promising Growth Potential with Strategic Manufacturing and Positive Clinical Results
Alec Stranahan, an analyst from Bank of America Securities, maintained the Buy rating on Meiragtx Holdings (MGTX – Research Report). The ...
precisionmedicineonline6d
MeiraGTx to Discuss Parkinson's Gene Therapy Data With Regulators, Planning Phase III Trial
The company said the latest positive safety, tolerability, and efficacy data will underpin discussions with regulators in the US, Europe, and Japan.